• 1
    Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006; 354: 1021-1030.
  • 2
    Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22: 414-423.
  • 3
    Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002; 100: 1168-1171.
  • 4
    Aapro MS, Dale DC, Blasi M, Sarokhan B, Ahmed F, Woodman RC. Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Support Care Cancer. 2006; 14: 1184-1194.
  • 5
    Coleman EA, Coon SK, Kennedy RL, et al. Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma. Oncol Nurs Forum. 2008; 35: E53-E61.
  • 6
    Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116( suppl 7A): 11S-26S.
  • 7
    Martino M, Oliva E, Console G, et al. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer. 2005; 13: 182-187.
  • 8
    Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299: 914-924.
  • 9
    Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009; 27: 4848-4857.
  • 10
    Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004; 18: 2044-2046.
  • 11
    Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004; 126: 715-721.
  • 12
    Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009; 27: 4865-4873.
  • 13
    Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25: 5490-5505.
  • 14
    Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006; 4: 838-869.
  • 15
    Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol. 2006; 59: 194-204.
  • 16
    Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol. 2008; 19( suppl 2): ii126-ii127.
  • 17
    Engert A. Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol. 2005; 16: 1584-1595.
  • 18
    Number Cruncher Statistical System (NCSS). Kaysville, UT; 2007.
  • 19
    Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98: 708-714.
  • 20
    Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104: 2822-2829.
  • 21
    Fullmer AC, Miller R. Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents. J Oncol Pharm Pract. 2009; 15: 167-173.
  • 22
    Anderson AJ, Krasnow SH, Boyer MW, et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest. 1989; 95: 71-75.
  • 23
    Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004; 9: 207-216.
  • 24
    Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol. 2009; 27: 4889-4894.
  • 25
    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001; 98: 1614-1615.
  • 26
    El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 2007; 97: 1031-1036.
  • 27
    Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009; 27( suppl 1): 63-74.
  • 28
    Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003; 4: 32-35.
  • 29
    Cavo M, Palumbo A, Bringhen S, et al. A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 3017.
  • 30
    Chen SL, Jiang B, Qiu LG, Yu L, Zhong YP, Gao W. Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. Anat Rec (Hoboken). 2010; 293: 1679-1684.
  • 31
    Lonial S, Richardson PG, San Miguel J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008; 143: 222-229.
  • 32
    Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008; 121: 567-571.
  • 33
    Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica. 2008; 93: 953-954.
  • 34
    Agnelli G, Gussoni G, Bianchini C, Verso M, Tonato M. A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: the PROTECHT Study. Blood (ASH Annual Meeting Abstracts). 2008;112: Abstract 6.
  • 35
    Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: results of the TOPIC studies. Journal of Thrombosis and Haemostasis. 2005; 3( suppl 1). Abstract OR059.
  • 36
    Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004; 22: 1944-1948.
  • 37
    Perry J, Rogers L, Laperriere N, et al. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol. 2007; 25: 2011.
  • 38
    Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006; 81: 758-767.
  • 39
    Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost. 2008; 99: 38-43.
  • 40
    Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol. 2009; 27: 4858-4864.
  • 41
    Mittelman M, Zeidman A, Kanter P, et al. Erythropoietin has an anti-myeloma effect—a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol. 2004; 72: 155-165.
  • 42
    Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362: 1255-1260.
  • 43
    Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer—meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009( 3): CD007303.
  • 44
    Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst. 2009; 101: 1633-1641.
  • 45
    Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010; 116: 22-26.